for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TherapeuticsMD Inc

TXMD.A

Latest Trade

1.60USD

Change

0.05(+3.23%)

Volume

2,222

Today's Range

1.54

 - 

1.61

52 Week Range

0.86

 - 

4.30

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.55
Open
1.57
Volume
2,222
3M AVG Volume
114.41
Today's High
1.61
Today's Low
1.54
52 Week High
4.30
52 Week Low
0.86
Shares Out (MIL)
272.29
Market Cap (MIL)
422.06
Forward P/E
-2.51
Dividend (Yield %)
--

Latest Developments

More

TherapeuticsMD Q2 Loss Per Share $0.19

TherapeuticsMD Says Q2 2020 Revenue Will Be Impacted Due To Covid-19

TherapeuticsMD Reports Appointment Of James C. D’Arecca As CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TherapeuticsMD Inc

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Industry

Biotechnology & Drugs

Contact Info

951 W Yamato Rd Ste 220

BOCA RATON, FL

33431-4440

United States

+1.561.9611900

https://www.therapeuticsmd.com/

Executive Leadership

Tommy G. Thompson

Independent Chairman of the Board

John C.K. Milligan

President, Secretary

Robert G. Finizio

Chief Executive Officer and Director

Brian A. Bernick

Co-Founder

James C. D'Arecca

Chief Financial Officer

Key Stats

2.22 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2017

-0.370

2018

-0.590

2019

-0.720

2020(E)

-0.625
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.75
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-104.60
Return on Equity (TTM)
-84.15

Latest News

Latest News

BRIEF-TherapeuticsMD Says Q2 2020 Revenue Will Be Impacted Due To Covid-19

* THERAPEUTICSMD INC - Q2 2020 REVENUE WILL BE IMPACTED DUE TO COVID.19

BRIEF-TherapeuticsMD Reports Appointment Of James C. D’Arecca As CFO

* THERAPEUTICSMD ANNOUNCES APPOINTMENT OF JAMES C. D’ARECCA AS CHIEF FINANCIAL OFFICER AND RETIREMENT OF DANIEL A. CARTWRIGHT AS CHIEF FINANCIAL OFFICER

BRIEF-TherapeuticsMD Reports First Quarter 2020 Results

* THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Therapeuticsmd Inc - On April 27, Co Received A Loan Pursuant To Paycheck Protection Program Under Cares Act

* THERAPEUTICSMD INC - ON APRIL 27, CO RECEIVED A LOAN PURSUANT TO PAYCHECK PROTECTION PROGRAM UNDER CARES ACT

BRIEF-Therapeuticsmd Inc - Does Not Anticipate A Shortage Of Its Products Due To Covid-19 At This Time

* THERAPEUTICSMD - STRONG PRELIMINARY Q1 2020 TOTAL NET REVENUE PROJECTED TO BE MORE THAN $11 MILLION

BRIEF-TherapeuticsMD Provides Business Update On Covid-19 Pandemic

* THERAPEUTICSMD PROVIDES BUSINESS UPDATE ON COVID-19 PANDEMIC

BRIEF-TherapeuticsMD Announces Q4 Loss Per Share Of $0.19

* THERAPEUTICSMD ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

BRIEF-Therapeuticsmd, Afaxys Enter Agreement To Expand Access To Annovera In The U.S. Public Health Sector

* THERAPEUTICSMD AND AFAXYS ENTER INTO AGREEMENT TO EXPAND ACCESS TO ANNOVERA® IN THE U.S. PUBLIC HEALTH SECTOR Source text for Eikon: Further company coverage:

IN BRIEF: TherapeuticsMD settles SEC probe over selective drug disclosures

TherapeuticsMD Inc will pay $200,000 to resolve charges by the Securities and Exchange Commission that the pharmaceutical company selectively shared information with analysts about an in-development drug without also disclosing it to the public.

FDA approves TherapeuticsMD's menopause drug

The U.S. Food and Drug Administration (FDA) approved TherapeuticsMD's oral hormone therapy for menopause symptoms such as hot flashes, sleep disturbances and night sweats, the company said on Monday.

FDA approves TherapeuticsMD's menopause drug

The U.S. Food and Drug Administration approved TherapeuticsMD's oral hormone therapy for menopause symptoms such as hot flashes, sleep disturbances and night sweats, the company said on Monday.

TherapeuticsMD's therapy for menopause-related condition gets approval

Women's healthcare company TherapeuticsMD Inc won its first-ever U.S. approval on Wednesday with the drug regulator clearing its hormone therapy for a painful condition triggered by menopause after rejecting it a year earlier.

FDA approves TherapeuticsMD's hormone therapy

The U.S. Food and Drug Administration approved TherapeuticsMD Inc's hormone therapy for a painful condition triggered by menopause, the women's health company said on Wednesday.

BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11

* THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR

* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR

BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR

BRIEF-TherapeuticsMD Q4 Loss Per Share $0.10

* THERAPEUTICSMD ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-TherapeuticsMD Submits New Drug Application For TX-001HR

* THERAPEUTICSMD ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TX-001HR

BRIEF-Therapeuticsmd Announces FDA Acceptance Of New Drug Application And PDUFA Date For TX-004HR

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-004HR

BRIEF-TherapeuticsMD reports Q3 loss per share of $0.07

* TherapeuticsMD announces third quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up